相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 129676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
D. Sargent et al.
EUROPEAN JOURNAL OF CANCER (2011)
Molecular Selection Trumps Clinical Selection
Frances A. Shepherd
JOURNAL OF CLINICAL ONCOLOGY (2011)
International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial
C. Gridelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study
A. Inoue et al.
EJC SUPPLEMENTS (2009)
Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib
Kazuyuki Tsujino et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Molecular predictive and prognostic markers in non-small-cell lung cancer
Linda E. Coate et al.
LANCET ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from southwest oncology group Randomized trials
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy
Patricia A. Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis
Kent R. Johnson et al.
LANCET ONCOLOGY (2006)
Measures of response: RECIST, WHO, and new alternatives
C. Carl Jaffe
JOURNAL OF CLINICAL ONCOLOGY (2006)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect
S Teramukai et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
End points and United States food and drug administration approval of oncology drugs
JR Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study
PJ Goodwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Clinical trial designs for cytostatic agents: Are new approaches needed?
EL Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
M Buyse et al.
LANCET (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
